RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (Globe Newswire) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call. Provides the latest financial and corporate information. Fourth quarter and full year 2023 results will be released on Wednesday, February 28, 2024 at 8:30 a.m. ET.
To register for the event and receive a dial-in number and unique PIN to access the live conference call, please register online by following this link. Although not required, we encourage you to join 10 minutes before the event starts. Live and archived webcasts can be viewed on the “Events & Presentations” page of the company's website (www.g1therapeutics.com). The webcast will be archived on the same page for 90 days after the event.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop next-generation products that improve the lives of people affected by cancer, including its first commercial product, COSELA® (trilaciclib). Developing and delivering treatments. The company is also evaluating treatments in combination with cytotoxic therapies and immunotherapies in areas of high unmet need, such as triple-negative breast cancer and extensive-stage small cell lung cancer. G1's goal is to bring innovative treatment advances to people living with cancer. G1 is based in Research Triangle Park, North Carolina. For more information, please visit http://www.g1therapeutics.com and follow us on X (formerly Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
G1 Therapeutics Contact Information:
Will Roberts
communication officer
Vice President of Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
